AxoGen ( (AXGN) ) just unveiled an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Axogen, Inc., a leader in peripheral nerve repair solutions, reported a notable 17.9% revenue increase for Q3 2024 at $48.6 million, alongside a decrease in net loss to $1.9 million from $4.1 million in the previous year. The company’s strategic advancements include FDA acceptance of its Biologics License Application for Avance Nerve Graft and promising engagement at industry events. Axogen aims to hit the high end of its revenue and gross margin guidance while maintaining its commitment to improving nerve repair standards globally.
Find detailed analytics on AXGN stock on TipRanks’ Stock Analysis page.